Literature DB >> 25514868

Radiosurgery for unruptured cerebral arteriovenous malformations in pediatric patients.

Dale Ding1, Zhiyuan Xu, Chun-Po Yen, Robert M Starke, Jason P Sheehan.   

Abstract

BACKGROUND: Unruptured cerebral arteriovenous malformations (AVMs) in pediatric patients (age <18 years) were excluded from A Randomized Trial of Unruptured AVMs (ARUBA). Therefore, the efficacy of radiosurgery for unruptured pediatric AVMs is poorly understood. The goal of this study is to determine the outcomes and define the predictors of obliteration following radiosurgery for unruptured AVMs in pediatric patients.
METHODS: We evaluated a prospective database, from 1989 to 2013, of AVM patients treated with radiosurgery at our institution. Patients with age less than 18 years at the time of radiosurgery, unruptured nidi, and at least 2 years of radiologic follow-up or AVM obliteration were selected for analysis. Statistical analyses were performed to determine actuarial obliteration rates and identify factors associated with obliteration.
RESULTS: In the 51 unruptured pediatric AVM patients included for analysis, the median age was 13 years, and the most common presentation was seizure in 53 %. The median nidus volume and radiosurgical margin dose were 3.2 cm(3) and 21.5 Gy, respectively. The median radiologic follow-up was 45 months. The actuarial AVM obliteration rates at 3, 5, and 10 years were 29 %, 54 %, and 72 %, respectively. In the multivariate Cox proportional hazards regression analysis, higher margin dose (P = 0.002), fewer draining veins (P = 0.038), and lower Virginia Radiosurgery AVM Scale (P = 0.003) were independent predictors of obliteration. Obliteration rates were significantly higher with a margin dose of at least 22 Gy (P = 0.003) and for nidi with 2 or fewer draining veins (P = 0.001). The incidences of radiologically evident, symptomatic, and permanent radiation-induced changes were 55 %, 16 %, and 2 %, respectively. The annual post-radiosurgery hemorrhage rate was 1.3 %, and the incidence of post-radiosurgery cyst formation was 2 %.
CONCLUSION: Radiosurgery affords a favorable risk to benefit profile for unruptured pediatric AVMs. Pediatric patients with unruptured AVMs merit further study to define an optimal management approach.

Entities:  

Mesh:

Year:  2014        PMID: 25514868     DOI: 10.1007/s00701-014-2305-4

Source DB:  PubMed          Journal:  Acta Neurochir (Wien)        ISSN: 0001-6268            Impact factor:   2.216


  6 in total

1.  Management of brain arteriovenous malformations.

Authors:  Sherri A Braksick; Jennifer E Fugate
Journal:  Curr Treat Options Neurol       Date:  2015-07       Impact factor: 3.598

2.  Surgical Approaches for Symptomatic Cerebral Cavernous Malformations of the Thalamus and Brainstem.

Authors:  Dale Ding; Robert M Starke; R Webster Crowley; Kenneth C Liu
Journal:  J Cerebrovasc Endovasc Neurosurg       Date:  2017-03-31

3.  Preoperative Embolization of Cerebral Arteriovenous Malformations with Silk Suture and Particles: Technical Considerations and Outcomes.

Authors:  Jordan R Conger; Dale Ding; Daniel M Raper; Robert M Starke; Christopher R Durst; Kenneth C Liu; Mary E Jensen; Avery J Evans
Journal:  J Cerebrovasc Endovasc Neurosurg       Date:  2016-06-30

4.  Sylvian Arteriovenous Malformation Resection and Associated Middle Cerebral Artery Aneurysm Clipping: Technical Nuances of Concurrent Surgical Treatment.

Authors:  Dale Ding; Thomas J Buell; Daniel M Raper; Ching-Jen Chen; Panagiotis Mastorakos; Kenneth C Liu; Dennis G Vollmer
Journal:  Cureus       Date:  2018-02-07

5.  Application of Multimodal Navigation together with Fluorescein Angiography in Microsurgical Treatment of Cerebral Arteriovenous Malformations.

Authors:  Shiyu Feng; Yanyang Zhang; Zhenghui Sun; Chen Wu; Zhe Xue; Yudong Ma; Jinli Jiang
Journal:  Sci Rep       Date:  2017-11-01       Impact factor: 4.379

6.  Comparison of the Long-term Efficacy and Safety of Gamma Knife Radiosurgery for Arteriovenous Malformations in Pediatric and Adult Patients.

Authors:  Hirotaka Hasegawa; Shunya Hanakita; Masahiro Shin; Mariko Kawashima; Wataru Takahashi; Osamu Ishikawa; Satoshi Koizumi; Hirofumi Nakatomi; Nobuhito Saito
Journal:  Neurol Med Chir (Tokyo)       Date:  2018-05-17       Impact factor: 1.742

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.